|Print Page Close Window|
Stockholder OverviewCorvus Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel immuno-oncology therapies that are designed to harness the immune system to attack cancer cells. Since we began operations in November 2014, we have built a pipeline of four immuno-oncology programs, three of which focus on the adenosine-cancer axis to modulate an immune response. ...
NASDAQ CRVS (Common Stock)
$11.16 - 1.34 (10.72%)
06/22/184:00 p.m. ETData provided by Nasdaq. Minimum 15 minutes delayed.
Corvus Pharmaceuticals to Present at Jefferies 2018 Global Healthcare Conference05/30/18
Corvus Pharmaceuticals Reports First Quarter 2018 Financial Results and Provides Business Update05/03/18
Corvus Pharmaceuticals Announces Initiation of Phase 1/1b Clinical Trial of Investigational Anti-CD73 Antibody, CPI-006, in Patients with Advanced Cancer04/26/18
There are currently no events scheduled.